E1305: A Phase 3, Randomized Trial of Chemotherapy with or without Bevacizumab with Recurrent or Metastatic Head and Neck Cancer

The purpose of the study is to find out whether adding a new drug (Bevacizumab) to the standart platinum-based chemotherapy will help improve the survival of patients whose head and neck cancer has either returned after chemotherapy or spread throughout the body.

Primary Sponsor:
Eastern Cooperative Oncology Group (ECOG)

Prinicipal Investigator:
Imad A.Tabbara, M.D.

Contact Phone:
(202) 741-2981

Are you interested in more information on this clinical trial?

First Name *
Last Name *
Email *
Street Address *
City *
State *
Zip Code *
Phone Number 
     
Verification Code *

Please type what you see (all uppercase):